KALV vs CAPR โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
KALV Captures Institutional Edge (2โ2 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to KalVista Pharmaceuticals, Inc. Common Stock (KALV) driven by superior Valuation, Momentum & Technical while CAPR counters with relative strength in Growth & Margin, Options & Structure. Fundamentally, KALV trades at 25.4x Forward P/E with -57.4% operating margin (+30.7% YoY revenue) versus CAPR at 78.7x Forward P/E and 0.0% operating margin (-7.9% YoY). In options structure, KALV sits in UNCLASSIFIED (31st %ile IV; Dealer Gamma Walls on Pro) against CAPR sits in CONSOLIDATION (89th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | KALV | CAPR | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.4B | $595.4M | Larger Scale | KALV |
| Trailing P/E Ratio Valuation | 25.4x | 78.7x | Lower Multiple | KALV |
| Forward P/E Ratio Valuation | 25.4x | 78.7x | Lower Multiple | KALV |
| Revenue Growth (YoY) Growth | +30.7% | -7.9% | Higher Growth | KALV |
| Operating Margin (TTM) Profitability | -57.4% | 0.0% | Higher Margin | CAPR |
| Net Profit Margin Profitability | -118.7% | 0.0% | Higher Margin | CAPR |
| Return on Equity (ROE) Capital Efficiency | -190.2% | -100.5% | Higher ROE | CAPR |
| 52-Week Range Position Momentum | 100% ($10โ$27) | 15% ($3โ$40) | Stronger Trend | KALV |
| Beta / 30D Volatility Risk Regime | 0.85ฮฒ ยท 2% Vol | 1.52ฮฒ ยท 152% Vol | Lower Realized Risk | KALV |
| Unified Institutional Score Composite Signal | 55.1 / 100 (HOLD) | 28.0 / 100 (SELL) | Higher Composite | KALV |